Plain-English translation of NCT07704099 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Duchenne Muscular Dystrophy research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new medication called to see if it can help people with Duchenne muscular dystrophy, a genetic condition that causes progressive muscle weakness and loss of strength. Researchers want to find out if the medication is safe and whether it can slow down or improve muscle function. You would receive this treatment alongside your current corticosteroid therapy (medication you may already be taking).
Duchenne muscular dystrophy is a serious condition with limited treatment options, and this medication is designed to work through a new mechanism to help preserve or improve muscle strength and function in people living with this disease.
You likely qualify if…
You likely don't qualify if…
The study lasts about 58 weeks total: a 6-week screening period to check if you qualify, 48 weeks of treatment where you'll receive along with your regular corticosteroid medication, and a 4-week safety follow-up period. During your time in the study, you'll have regular clinic visits where doctors will monitor your muscle strength, safety, and overall health through physical tests and check-ups.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
New Zealand